The agency, expressing concerns about hallucinations, suicidal thoughts
and psychotic and violent behavior associated with methylphenidate
products, says it plans to make labeling changes for that class of
drugs used to treat attention deficit hyperactivity disorder. Those
include Johnson & Johnson's Concerta and Ritalin from Novartis. The
agency said it also is reviewing adverse event reports on Eli Lilly's
Strattera and Shire's Adderall. Company representatives were not available for comment.